{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:03:14Z","timestamp":1778857394817,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,5,23]],"date-time":"2004-05-23T00:00:00Z","timestamp":1085270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1038\/nm1052","type":"journal-article","created":{"date-parts":[[2004,5,23]],"date-time":"2004-05-23T20:54:14Z","timestamp":1085345654000},"page":"594-601","source":"Crossref","is-referenced-by-count":803,"title":["mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways"],"prefix":"10.1038","volume":"10","author":[{"given":"Pradip K","family":"Majumder","sequence":"first","affiliation":[]},{"given":"Phillip G","family":"Febbo","sequence":"additional","affiliation":[]},{"given":"Rachel","family":"Bikoff","sequence":"additional","affiliation":[]},{"given":"Raanan","family":"Berger","sequence":"additional","affiliation":[]},{"given":"Qi","family":"Xue","sequence":"additional","affiliation":[]},{"given":"Louis M","family":"McMahon","sequence":"additional","affiliation":[]},{"given":"Judith","family":"Manola","sequence":"additional","affiliation":[]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[]},{"given":"Timothy J","family":"McDonnell","sequence":"additional","affiliation":[]},{"given":"Todd R","family":"Golub","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Loda","sequence":"additional","affiliation":[]},{"given":"Heidi A","family":"Lane","sequence":"additional","affiliation":[]},{"given":"William R","family":"Sellers","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2004,5,23]]},"reference":[{"key":"BFnm1052_CR1","doi-asserted-by":"publisher","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","volume":"273","author":"T Maehama","year":"1998","unstructured":"Maehama, T. & Dixon, J.E. The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375\u201313378 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnm1052_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.278.5338.687","volume":"278","author":"L del Peso","year":"1997","unstructured":"del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687\u2013689 (1997).","journal-title":"Science"},{"key":"BFnm1052_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/19328","volume":"398","author":"GJ Kops","year":"1999","unstructured":"Kops, G.J. et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398, 630\u2013634 (1999).","journal-title":"Nature"},{"key":"BFnm1052_CR4","doi-asserted-by":"publisher","first-page":"8969","DOI":"10.1128\/MCB.20.23.8969-8982.2000","volume":"20","author":"N Nakamura","year":"2000","unstructured":"Nakamura, N. et al. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol. 20, 8969\u20138982 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm1052_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. & Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785\u2013789 (1995).","journal-title":"Nature"},{"key":"BFnm1052_CR6","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1101\/gad.13.24.3244","volume":"13","author":"DC Goberdhan","year":"1999","unstructured":"Goberdhan, D.C., Paricio, N., Goodman, E.C., Mlodzik, M. & Wilson, C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico\/PI3-kinase signaling pathway. Genes Dev. 13, 3244\u20133258 (1999).","journal-title":"Genes Dev."},{"key":"BFnm1052_CR7","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1101\/gad.845700","volume":"14","author":"S Oldham","year":"2000","unstructured":"Oldham, S., Montagne, J., Radimerski, T., Thomas, G. & Hafen, E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 14, 2689\u20132694 (2000).","journal-title":"Genes Dev."},{"key":"BFnm1052_CR8","doi-asserted-by":"publisher","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat, M.S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc. Natl. Acad. Sci. USA 98, 10314\u201310319 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1052_CR9","doi-asserted-by":"publisher","first-page":"10320","DOI":"10.1073\/pnas.171060098","volume":"98","author":"K Podsypanina","year":"2001","unstructured":"Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice. Proc. Natl. Acad. Sci. USA 98, 10320\u201310325 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1052_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.98.1.136","volume":"98","author":"M Aoki","year":"2001","unstructured":"Aoki, M., Blazek, E. & Vogt, P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 98, 136\u2013141 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1052_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","volume":"10","author":"BD Manning","year":"2002","unstructured":"Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J. & Cantley, L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol. Cell 10, 151\u2013162 (2002).","journal-title":"Mol. Cell"},{"key":"BFnm1052_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ncb847","volume":"4","author":"X Gao","year":"2002","unstructured":"Gao, X. et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4, 699\u2013704 (2002).","journal-title":"Nat. Cell Biol."},{"key":"BFnm1052_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1101\/gad.901101","volume":"15","author":"X Gao","year":"2001","unstructured":"Gao, X. & Pan, D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15, 1383\u2013192 (2001).","journal-title":"Genes Dev."},{"key":"BFnm1052_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0092-8674(01)00333-6","volume":"105","author":"CJ Potter","year":"2001","unstructured":"Potter, C.J., Huang, H. & Xu, T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105, 357\u2013368 (2001).","journal-title":"Cell"},{"key":"BFnm1052_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C. & Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259\u20131268 (2003).","journal-title":"Curr. Biol."},{"key":"BFnm1052_CR16","first-page":"295","volume":"3","author":"S Huang","year":"2002","unstructured":"Huang, S. & Houghton, P.J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Invest. Drugs 3, 295\u2013304 (2002).","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"BFnm1052_CR17","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.1073\/pnas.1232229100","volume":"100","author":"PK Majumder","year":"2003","unstructured":"Majumder, P.K. et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. USA 100, 7841\u20137846 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1052_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00007691-200202000-00010","volume":"24","author":"B Nashan","year":"2002","unstructured":"Nashan, B. Early clinical experience with a novel rapamycin derivative. Ther. Drug Monit. 24, 53\u201358 (2002).","journal-title":"Ther. Drug Monit."},{"key":"BFnm1052_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/emboj\/19.3.434","volume":"19","author":"B Raught","year":"2000","unstructured":"Raught, B. et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J. 19, 434\u2013444 (2000).","journal-title":"EMBO J."},{"key":"BFnm1052_CR20","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/sj.onc.1203571","volume":"19","author":"EM Bruckheimer","year":"2000","unstructured":"Bruckheimer, E.M. et al. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene 19, 2404\u20132412 (2000).","journal-title":"Oncogene"},{"key":"BFnm1052_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V.K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"BFnm1052_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S0006-2952(02)01168-1","volume":"64","author":"G Semenza","year":"2002","unstructured":"Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64, 993\u2013998 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"BFnm1052_CR23","volume-title":"Prostate Cancer Principles and Practice","author":"WR Sellers","year":"2002","unstructured":"Sellers, W.R. & Sawyers, C.A. Somatic genetics of prostate cancer: oncogenes and Tumor Suppressors. in Prostate Cancer Principles and Practice (ed. Kantoff, P.) (Lippincott Williams & Wilkins, Philadelphia, USA, 2002)."},{"key":"BFnm1052_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).","journal-title":"Science"},{"key":"BFnm1052_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/5042","volume":"21","author":"L Shayesteh","year":"1999","unstructured":"Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99\u2013102 (1999).","journal-title":"Nat. Genet."},{"key":"BFnm1052_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0092-8674(02)01001-2","volume":"111","author":"J Debnath","year":"2002","unstructured":"Debnath, J. et al. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111, 29\u201340 (2002).","journal-title":"Cell"},{"key":"BFnm1052_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1083\/jcb.200304159","volume":"163","author":"J Debnath","year":"2003","unstructured":"Debnath, J., Walker, S.J. & Brugge, J.S. Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J. Cell. Biol. 163, 315\u2013326 (2003).","journal-title":"J. Cell. Biol."},{"key":"BFnm1052_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel, H.G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332\u2013337 (2004).","journal-title":"Nature"},{"key":"BFnm1052_CR29","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1091\/mbc.01-12-0584","volume":"13","author":"AL Edinger","year":"2002","unstructured":"Edinger, A.L. & Thompson, C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276\u20132288 (2002).","journal-title":"Mol. Biol. Cell"},{"key":"BFnm1052_CR30","first-page":"6940","volume":"52","author":"TJ McDonnell","year":"1992","unstructured":"McDonnell, T.J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940\u20136944 (1992).","journal-title":"Cancer Res."},{"key":"BFnm1052_CR31","first-page":"389","volume":"2","author":"Y Furuya","year":"1996","unstructured":"Furuya, Y., Krajewski, S., Epstein, J.I., Reed, J.C. & Isaacs, J.T. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res. 2, 389\u2013398 (1996).","journal-title":"Clin. Cancer Res."},{"key":"BFnm1052_CR32","first-page":"1567","volume":"148","author":"M Krajewska","year":"1996","unstructured":"Krajewska, M. et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148, 1567\u20131576 (1996).","journal-title":"Am. J. Pathol."},{"key":"BFnm1052_CR33","first-page":"390","volume":"143","author":"M Colombel","year":"1993","unstructured":"Colombel, M. et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143, 390\u2013400 (1993).","journal-title":"Am. J. Pathol."},{"key":"BFnm1052_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1046\/j.1464-410x.2000.00388.x","volume":"85","author":"S Baltaci","year":"2000","unstructured":"Baltaci, S., Orhan, D., Ozer, G., Tolunay, O. & Gogous, O. Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. BJU Int. 85, 155\u2013159 (2000).","journal-title":"BJU Int."},{"key":"BFnm1052_CR35","first-page":"4291","volume":"59","author":"ME McMenamin","year":"1999","unstructured":"McMenamin, M.E. et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59, 4291\u20134296 (1999).","journal-title":"Cancer Res."},{"key":"BFnm1052_CR36","first-page":"204","volume":"58","author":"H Suzuki","year":"1998","unstructured":"Suzuki, H. et al. Interfocal heterogeneity of PTEN\/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204\u2013209 (1998).","journal-title":"Cancer Res."},{"key":"BFnm1052_CR37","doi-asserted-by":"publisher","first-page":"38830","DOI":"10.1074\/jbc.M103632200","volume":"276","author":"H Huang","year":"2001","unstructured":"Huang, H. et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 276, 38830\u201338836 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnm1052_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3816\/CBC.2003.n.018","volume":"4","author":"MM Mita","year":"2003","unstructured":"Mita, M.M., Mita, A. & Rowinsky, E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 4, 126\u2013137 (2003).","journal-title":"Clin. Breast Cancer"},{"key":"BFnm1052_CR39","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","volume":"19","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo, M. & Rowinsky, E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680\u20136686 (2000).","journal-title":"Oncogene"},{"key":"BFnm1052_CR40","first-page":"3920","volume":"7","author":"KN Chi","year":"2001","unstructured":"Chi, K.N. et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 7, 3920\u20133927 (2001).","journal-title":"Clin. Cancer Res."},{"key":"BFnm1052_CR41","first-page":"679","volume":"8","author":"MJ Morris","year":"2002","unstructured":"Morris, M.J. et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 8, 679\u2013683 (2002).","journal-title":"Clin. Cancer Res."},{"key":"BFnm1052_CR42","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1200\/JCO.1999.17.7.2213","volume":"17","author":"RS DiPaola","year":"1999","unstructured":"DiPaola, R.S. et al. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J. Clin. Oncol. 17, 2213\u20132218 (1999).","journal-title":"J. Clin. Oncol."},{"key":"BFnm1052_CR43","first-page":"19","volume":"26","author":"D Friedland","year":"1999","unstructured":"Friedland, D. et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin. Oncol. 26, 19\u201323 (1999).","journal-title":"Semin. Oncol."},{"key":"BFnm1052_CR44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721\u2013732 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm1052_CR45","first-page":"299","volume":"279","author":"RT Abraham","year":"2004","unstructured":"Abraham, R.T. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr. Top. Microbiol. Immunol. 279, 299\u2013319 (2004).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"BFnm1052_CR46","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson, C.C. et al. Regulation of hypoxia-inducible factor 1\u03b1 expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004\u20137014 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm1052_CR47","first-page":"1541","volume":"60","author":"H Zhong","year":"2000","unstructured":"Zhong, H. et al. Modulation of hypoxia-inducible factor 1\u03b1 expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541\u20131545 (2000).","journal-title":"Cancer Res."},{"key":"BFnm1052_CR48","doi-asserted-by":"publisher","first-page":"27975","DOI":"10.1074\/jbc.M204152200","volume":"277","author":"C Treins","year":"2002","unstructured":"Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G.L. & Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase\/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277, 27975\u201327981 (2002).","journal-title":"J. Biol. Chem."},{"key":"BFnm1052_CR49","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","volume":"4","author":"JB Brugarolas","year":"2003","unstructured":"Brugarolas, J.B., Vazquez, F., Reddy, A., Sellers, W.R. & Kaelin, W.G., Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4, 147\u2013158 (2003).","journal-title":"Cancer Cell"},{"issue":"suppl. 1","key":"BFnm1052_CR50","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1111\/j.1432-2277.1994.tb01363.x","volume":"7","author":"S Taesch","year":"1994","unstructured":"Taesch, S. & Niese, D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Transpl. Int. 7 (suppl. 1), S263\u2013S266 (1994).","journal-title":"Transpl. Int."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm1052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1052","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:02:20Z","timestamp":1684432940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm1052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,23]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["BFnm1052"],"URL":"https:\/\/doi.org\/10.1038\/nm1052","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1020029.228476","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,23]]}}}